Unlock instant, AI-driven research and patent intelligence for your innovation.

A cinnamic acid derivative with aldose reductase inhibitory activity and its preparation method and application

A cinnamic acid derivative, a technology for inhibiting activity, applied in the field of medicine, can solve the problems of death, inaccurate curative effect, large toxic and side effects, etc.

Active Publication Date: 2019-11-08
广州药本君安医药科技股份有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among them, arestat and sobinil were announced to be discontinued due to their large toxic and side effects, and ponastat was announced to be discontinued due to inaccurate curative effect; torristat was announced to be discontinued in 1997 due to severe liver toxicity and death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A cinnamic acid derivative with aldose reductase inhibitory activity and its preparation method and application
  • A cinnamic acid derivative with aldose reductase inhibitory activity and its preparation method and application
  • A cinnamic acid derivative with aldose reductase inhibitory activity and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Example 1: Preparation of novel cinnamic acid derivatives with aldose reductase inhibitory activity

[0077] 1.1.3-N-(N-acetyl-O-benzyl-D-seryl)-α-cyano-3,4-dihydroxycinnamoylpropanediamide preparation

[0078] It includes the following five steps:

[0079] (1) Synthesis of compound α-cyano-3,4-dihydroxybenzoic acid: Weigh 138 mg (1.0 mmol) of 3,4-dihydroxybenzaldehyde into a dry 50 mL round-bottomed flask, add 85 mg of cyanoacetic acid ( 1.0 mmol), 15.4 mg (0.2 mmol) of ammonium acetate, 48 mg (0.8 mmol) of glacial acetic acid was weighed by syringe and added to the reaction system, then 10 mL of toluene was added as a solvent, and a small water separator, a condenser tube and a drying tube were connected to the reaction flask. The reaction was stirred and refluxed in an oil bath at 120°C for 18h. After the reaction was completed, the temperature was lowered to room temperature, then allowed to stand at low temperature, filtered, and the filter cake was washed three ...

Embodiment 2

[0158] Example 2: Inhibitory activity of the compound synthesized in Example 1 on aldose reductase enzyme

[0159] In this example, aldose reductase (AR), reduced coenzyme II (NADPH) and DL-glyceraldehyde were purchased from Sigma Company; Epalrestat was purchased from Tokyo Chemical Industry Co., Ltd.

[0160] Experimental steps: The enzyme reaction system was carried out on a 96-well plate. The reaction system included: PBS buffer (pH=6.2) 100 μL, 1.5 mmol / L NADPH 20 μL, 100 mmol / L DL-glyceraldehyde 20 μL, different concentrations (Epalrestat or tested sample) solution 20 μL, AR diluent 20 μL, distilled water 20 μL. The blank control group, standard control group, and enzyme metabolism group were set up in the experiment, as shown in Table 2-1.

[0161] Table 2-1. Grouping and Administration Table

[0162]

[0163] Note: All the above volume units are in μL.

[0164] After the above liquid was incubated at 37°C for 5min, except for the blank vehicle group, 20 μL of AR ...

Embodiment 3

[0172] Example 3: In vitro antioxidant activity of the compounds synthesized in Example 1

[0173] In this example, Trolox (6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylicacid); 1,1-diphenyl-2-picrylhydrazyl (DPPH) were purchased from Sigma Company.

[0174] Experimental steps: The reaction system was carried out on a 96-well plate, 40 μL of each test solution was added to the 96-well plate, and then 160 μL of DPPH solution was added in parallel to each well. At the same time, the control group (40 μL methanol + 160 μL DPPH) and the blank group (40 μL test substance + 160 μL methanol) were set. Shake for 1 min to make it evenly mixed, place the 96-well plate in the dark for 0.5 h, and quickly put the plate into the microplate reader with a detection wavelength of 517 nm. The final absorbance (A) value was measured, and each sample was tested three times in parallel, and the average value was taken. The formula for calculating the clearance rate is as follows:

[0175] Fre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a cinnamic acid derivative with aldose reductase inhibitory activity, a preparation method thereof and an application of the cinnamic acid derivative in the preparation of medicines for treating diabetes complications and diseases caused by oxidative stress. The structure of the compound is shown in Formula I. The preparation method comprises: first reacting substituted benzaldehyde with substituted acetic acid or its anhydride to obtain substituted cinnamic acid, and then reacting with N-tert-butoxyacyl-protected diamine compounds to obtain N-tert-butoxyacyl-protected substituted cinnamoyl diamine. The compound reacts with natural or unnatural N-acyl α-amino acid to obtain a cinnamic acid derivative after deprotecting tert-butoxyacyl group. The compound of the present invention has excellent inhibitory activity on aldose reductase and excellent antioxidant activity, and can be applied to the preparation and treatment of diabetic complications, especially diabetic retinopathy, diabetic senile dementia, nerve terminal disorders and other diseases, as well as those caused by oxidative stress. medicines for diseases.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a cinnamic acid derivative with aldose reductase inhibitory activity and a preparation method thereof, and the application of the cinnamic acid derivative in the preparation of a medicine for treating diabetic complications and diseases caused by oxidative stress . Background technique [0002] Diabetes Mellitus (DM) is an endocrine and metabolic syndrome characterized by hyperglycemia and glucosuria caused by insufficient insulin secretion or insulin resistance in the body. According to statistics from the International Diabetes Federation (IDF) in 2013, the number of people with diabetes worldwide is about 382 million, and this number is expected to increase to 592 million by 2035. my country is one of the countries with the largest number of diabetic patients, with approximately 98 million patients aged 20-79, and it is expected to increase to 143 million by 2035. Therefo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07C255/41C07C253/30C07D207/16C07C237/22C07C231/14A61K31/165A61K31/277A61K31/40A61P3/10
CPCC07C231/14C07C237/22C07C253/30C07C255/41C07D207/16
Inventor 陈河如袁盛李艳冰李怡芳何蓉蓉
Owner 广州药本君安医药科技股份有限公司